Delivery Order SPE2DB20D3103-SPE2DB25FP7C3
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,270.92 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10-count unit dose packaging) with an ultimate completion date of August 1, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through an open process. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication,...
- The Defense Logistics Agency awarded a $4,831.85 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packaging (10 tablets per dose). This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded contract. The order is scheduled for completion by July 29, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of UBRELVY 50 mg tablets in unit dose packaging (10 count). This order, valued at $5,439.62 with a firm fixed price structure, represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets in unit dose packages of 10, valued at $1,595.01. This competitively awarded, firm fixed-price delivery order was issued on July 24, 2025, with an ultimate completion date of July 25, 2025. The contract involves no set-aside designation and identifies AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania as the place of performance. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $1,048.62 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16 unit-dose tablets) on July 25, 2025, with an ultimate completion date of July 28, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor, with performance occurring at its corporate office location in the same city....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of UBRELVY 50 mg tablets in unit-dose packaging (10 units per package). This competitive award, valued at $30,906.84, represents a firm fixed-price delivery order with an ultimate completion date of July 25, 2025. The contract carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY (Ubrogepant) 100 mg tablets, unit dose packages of 10, valued at $1,158.25 with a firm fixed price structure. This award, issued on July 21, 2025, represents a non-set-aside competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to the contractor's distribution facility in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $4,357.50 to AmerisourceBergen Drug Corp for the supply of UBRELVY 100 mg tablets (unit dose, 10-count packages) on July 18, 2025, with an ultimate completion date of July 21, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award is a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $3,392.62 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16-count unit dose packaging) on July 21, 2025, with completion scheduled for July 22, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor...
- AmerisourceBergen Drug Corp was awarded a delivery order on July 30, 2025, by the Defense Logistics Agency (DLA) for UBRELVY 100 MG tablets in unit dose packaging of 10 units, with a ceiling value of $1,009.99. This is a firm fixed price delivery order with an ultimate completion date of July 31, 2025, and represents a non-competitive procurement utilizing an existing contract vehicle. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP7C3Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,109.38 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10 unit-dose packages), with completion scheduled for August 1, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a prescription medication used for migraine treatment, representing one of numerous pharmaceutical products supplied through the federal medical supply chain. This delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves critical medical procurement needs for military and veteran healthcare systems, supplying an extensive portfolio of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The company's federal contract awards with DLA demonstrate its capability to fulfill diverse pharmaceutical requirements through competitive procurement processes with consistent firm fixed-price delivery order structures.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 7/31/25 |